Prognostic significance of synaptophysin in stage I of squamous carcinoma and adenocarcinoma of the lung

Cancer

Volumn 110, Issue 8, 2007, Pages 1776-1781

  González Aragoneses, Federico ^a,b   Moreno Mata, Nicolás ^a,b   Cebollero Presmanes, María ^b   García Yuste, Mariano ^c   Cañizares Carretero, Miguel Ángel ^d   Molins López Rodó, Laureano ^e,f   Quevedo Losada, Santiago ^g   Torres Lanzas, Juan ^h,i   Álvarez Fernández, Emilio ^a,b   Almaraz, Ana ^c   Muñoz, María F ^c   Travis, William D ^j   Battafarano, Richard ^k   Fuentes, Pierre ^l  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d Xeral Hospital   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f Sagrado Corazon Hospital   (Spain)

^g Insular Hospital   (Spain)

^h UNIVERSITY OF MURCIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k WASHINGTON UNIVERSITY   (United States)

^l University Hospital of Marseille   (France)

more..

Author keywords

Immunohistochemistry; Neuroendocrine differentiation; Squamous carcinoma and adenocarcinoma of the lung; Survival

Indexed keywords

SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; SYNAPTOPHYSIN;

EID: 35048862036     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22985     Document Type: Article

References (20)

1. Read RC, Yoder G, Schaeffer RC. Survival after conservative resection for T1N0M0 non-small cell lung cancer. Ann Thorac Surg. 1990;49:391-398.
2. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumours in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120-129.
3. Travis WD, Colby TV, Corrin B, et al. Histological typing of lung and pleural tumours. WHO International Histological Classification of Tumours. Berlin: Springer; 1999.
4. Brambilla E. Large cell carcinoma. Pathology and genetics. In: Travis W, Brambilla E, Muller-Hermelink, Harris CG, eds. Tumours of the Lung. Lyon, France: IARC Press; 2004:45-50.
5. Hiroshima K, Iyoda A, Shibuya K, et al. Prognostic significance of neuroendocrine differentiation in adenocarcinoma of the lung. Ann Thorac Surg. 2002;73:1732-1735.
6. Linnoila RI, Mulshine JL, Steinberg SM, et al. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol. 1988;90:641-652.
7. Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46:195-201.
8. Carnaghi C, Rimassa L, Garassino I, Santoro A. Clinical significance of neuroendocrine phenotype in non-small-cell lung cancer. Ann Oncol. 2001;12:S119-123.
9. Garcia-Yuste M, Matilla JM, Alvarez-Gago T, et al. Prognostic factors in neuroendocrine lung tumours: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumours of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg. 2000;70:258-263.
10. Sundaresan V, Reeve JG, Stenning S, et al. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer. 1991;64:333-338.
11. Poola I, Graziano SL. Expression of NSE, Chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res. 1998;17:165-173.
12. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol. 2000;31:980-987.
13. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer. 1993;10:209-219.
14. Graziano SL, Tatum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res. 1994;54:2908-2913.
15. Schleusener JT, Tazelaar HD, Jung SH, et al. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. Cancer. 1996;77:1284-1291.
16. Cebollero-Presmanes M. Estudio de la historia natural de los carcinomas pulmonares no microciticos con diferenciacion neuroendocrina oculta. Tesis Doctoral. Universidad Complutense de Madrid, 2004.
17. Graziano SL, Mazid R, Newman N, et al. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. J Clin Oncol. 1989;7:1398-1406.
18. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma. Cancer. 2003;97:2487-2497.
19. Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation - an entity of no clinical prognostic significance. Am J Surg Pathol. 2007;31:26-32.
20. Iyoda A, Hiroshima K, Moriya Y, et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma. Ann Thorac Surg. 2006;82:1802-1807.